A detailed history of Octagon Capital Advisors LP transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 360,000 shares of KYMR stock, worth $23.4 Million. This represents 6.64% of its overall portfolio holdings.

Number of Shares
360,000
Previous 266,000 35.34%
Holding current value
$23.4 Million
Previous $11.6 Million 75.53%
% of portfolio
6.64%
Previous 4.41%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$37.68 - $58.5 $3.54 Million - $5.5 Million
94,000 Added 35.34%
360,000 $20.4 Million
Q2 2025

Aug 14, 2025

BUY
$21.05 - $48.6 $5.6 Million - $12.9 Million
266,000 New
266,000 $11.6 Million
Q3 2021

Nov 15, 2021

SELL
$47.8 - $66.66 $4.78 Million - $6.67 Million
-100,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$31.08 - $51.95 $3.11 Million - $5.2 Million
100,000 New
100,000 $4.85 Million

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $3.55B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.